The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
Huang-Shen Lin,1,2 Chun-Wen Cheng,3 Ming-Shyan Lin,4 Yen-Li Chou,5 Pey-Jium Chang,2 Jing-Chi Lin,6 Jung-Jr Ye3 1Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-03-01
|
| Series: | Clinical Interventions in Aging |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-clinical-outcomes-of-oldest-old-patients-with-tuberculosis-treated-peer-reviewed-article-CIA |
| _version_ | 1824014831705915392 |
|---|---|
| author | Lin HS Cheng CW Lin MS Chou YL Chang PJ Lin JC Ye JJ |
| author_facet | Lin HS Cheng CW Lin MS Chou YL Chang PJ Lin JC Ye JJ |
| author_sort | Lin HS |
| collection | DOAJ |
| description | Huang-Shen Lin,1,2 Chun-Wen Cheng,3 Ming-Shyan Lin,4 Yen-Li Chou,5 Pey-Jium Chang,2 Jing-Chi Lin,6 Jung-Jr Ye3 1Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, 3Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, 4Division of Cardiology, Chang Gung Memorial Hospital, Yunlin, 5Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 6Division of Allergy and Immunology and Rheumatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan Objectives: To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens. Design: A retrospective chart review study. Setting: A 1,200-bed tertiary teaching hospital in southwest Taiwan. Participants: We conducted a retrospective observational study between January 1, 2005 and December 31, 2011. Seven hundred adult patients (aged ≥18 years) with TB treated with RIP-containing anti-TB regimens were reviewed, including 161 oldest old patients. Outcome measures: Clinical outcomes included clinical responsiveness and microbiological eradication. Adverse outcomes included drug-induced hepatitis, and other symptoms included gastrointestinal upset (eg, abdominal pain, vomiting, diarrhea, or dyspepsia), skin rash, joint pain, and hyperuricemia. Results: Compared with the non-oldest old adult patients, the oldest old patients more frequently had hepatitis (P=0.014), gastrointestinal upset (P=0.029), and unfavorable outcomes (P<0.001). In a multivariate analysis, hepatitis during treatment (adjusted odds ratio: 3.482, 95% confidence interval: 1.537–7.885; P<0.003) and oldest old age (adjusted odds ratio: 5.161, 95% confidence interval: 2.294–11.613; P<0.010) were independent risk factors for unfavorable outcomes. In the oldest old patients with hepatitis, rifampicin use was more common in the favorable outcome group than in the unfavorable outcome group (100% vs 37.5%; P=0.001). Conclusion: The oldest old age and hepatitis during RIP treatment were associated with unfavorable outcomes. For the oldest old patients with TB having hepatitis during treatment, rifampicin rechallenge and use might benefit the treatment outcome. Keywords: hepatitis, refampicin, adverse effect |
| first_indexed | 2024-12-18T22:19:52Z |
| format | Article |
| id | doaj.art-443d666efdfd412cb8a878c5fa45e7af |
| institution | Directory Open Access Journal |
| issn | 1178-1998 |
| language | English |
| last_indexed | 2024-12-18T22:19:52Z |
| publishDate | 2016-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Interventions in Aging |
| spelling | doaj.art-443d666efdfd412cb8a878c5fa45e7af2022-12-21T20:49:43ZengDove Medical PressClinical Interventions in Aging1178-19982016-03-01Volume 1129930625959The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamideLin HSCheng CWLin MSChou YLChang PJLin JCYe JJHuang-Shen Lin,1,2 Chun-Wen Cheng,3 Ming-Shyan Lin,4 Yen-Li Chou,5 Pey-Jium Chang,2 Jing-Chi Lin,6 Jung-Jr Ye3 1Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, 3Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, 4Division of Cardiology, Chang Gung Memorial Hospital, Yunlin, 5Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 6Division of Allergy and Immunology and Rheumatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan Objectives: To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens. Design: A retrospective chart review study. Setting: A 1,200-bed tertiary teaching hospital in southwest Taiwan. Participants: We conducted a retrospective observational study between January 1, 2005 and December 31, 2011. Seven hundred adult patients (aged ≥18 years) with TB treated with RIP-containing anti-TB regimens were reviewed, including 161 oldest old patients. Outcome measures: Clinical outcomes included clinical responsiveness and microbiological eradication. Adverse outcomes included drug-induced hepatitis, and other symptoms included gastrointestinal upset (eg, abdominal pain, vomiting, diarrhea, or dyspepsia), skin rash, joint pain, and hyperuricemia. Results: Compared with the non-oldest old adult patients, the oldest old patients more frequently had hepatitis (P=0.014), gastrointestinal upset (P=0.029), and unfavorable outcomes (P<0.001). In a multivariate analysis, hepatitis during treatment (adjusted odds ratio: 3.482, 95% confidence interval: 1.537–7.885; P<0.003) and oldest old age (adjusted odds ratio: 5.161, 95% confidence interval: 2.294–11.613; P<0.010) were independent risk factors for unfavorable outcomes. In the oldest old patients with hepatitis, rifampicin use was more common in the favorable outcome group than in the unfavorable outcome group (100% vs 37.5%; P=0.001). Conclusion: The oldest old age and hepatitis during RIP treatment were associated with unfavorable outcomes. For the oldest old patients with TB having hepatitis during treatment, rifampicin rechallenge and use might benefit the treatment outcome. Keywords: hepatitis, refampicin, adverse effecthttps://www.dovepress.com/the-clinical-outcomes-of-oldest-old-patients-with-tuberculosis-treated-peer-reviewed-article-CIATuberculosisOldest oldAdverse effect |
| spellingShingle | Lin HS Cheng CW Lin MS Chou YL Chang PJ Lin JC Ye JJ The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide Clinical Interventions in Aging Tuberculosis Oldest old Adverse effect |
| title | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide |
| title_full | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide |
| title_fullStr | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide |
| title_full_unstemmed | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide |
| title_short | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide |
| title_sort | clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin isoniazid and pyrazinamide |
| topic | Tuberculosis Oldest old Adverse effect |
| url | https://www.dovepress.com/the-clinical-outcomes-of-oldest-old-patients-with-tuberculosis-treated-peer-reviewed-article-CIA |
| work_keys_str_mv | AT linhs theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT chengcw theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linms theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT chouyl theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT changpj theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linjc theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT yejj theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linhs clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT chengcw clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linms clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT chouyl clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT changpj clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linjc clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT yejj clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide |